Table 3.
Detection of anti-EBV-dUTPase antibodies (Ab) in patients with DLBCL or CLL.
| Clinical Status | Gender | % Positive EBV dUTPase Ab a | % Abnormal Reactive Ab Pattern to EBV (ARP_EBV) b | % ARP_EBV & dUTPase Seropositive c |
|---|---|---|---|---|
| Controls | Females | 11.67 (32/268) | 22.22 (10/45) | 8.88 (4/45) |
| Males | 13.98 (23/163) | 11.36 (5/44) | 4.54 (2/44) | |
| DLBCL | Females | 42.86 (9/21) | 33.33 (7/21) | 14.28 (3/21) |
| Males | 26.66 (4/15) | 20.00 (3/15) | 0.00 (0/15) | |
| CLL | Females | 34.37 (11/32) | 53.12 (17/32) | 18.75 (6/32) |
| Males | 44.12 (15/34) | 20.59 (7/34) | 14.70 (5/34) |
a dUTPase neutralizing assays were performed as described previously [44]. Values in parentheses represent the number of positive sera in either cases or controls/total sera. The total number of control sera (n = 431) include 89 samples from the EPILYMPH case-control study [58] as well as 352 samples from other published studies [44,45,48]. b Individuals’ sera exhibiting an abnormal reactive Ab pattern to EBV (ARP_EBV) was determined by de Sanjose et al., as part of the EPILYMPH case-control previously published study [58]. Values represent the percentage of sera samples exhibiting EBV-IgG reactivity to combined immuno-dominant epitopes of EBNA1 and VCA-p18-based ELISA assays and abnormal reactivity/intensity score on immunoblots to EBV antigens (ex: EAd-p47/54, EAd-p138) other than/besides EBNA1, VCA-p40, VAC-p18, and ZEBRA predominantly recognized by healthy EBV immunocompetent individuals [58]. Values in parentheses represent the number of individuals exhibiting increased/abnormal Ab responses to EBV proteins in either cases or controls sera/total sera. c Values represent the percentage of sera samples that were positive for anti-EBV-dUTPase antibodies and also had increased/abnormal EBV reactivity. Values in parentheses represent the number of positive sera in either case or controls/total sera.